Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00546780 | A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse | PHASE3 | COMPLETED | 31 | — | — | Feb 1, 2008 | Mar 1, 2010 | Jun 28, 2011 | 19 | United States, Canada |
| NCT00514371 | A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma | PHASE2 | COMPLETED | 22 | — | — | Aug 1, 2007 | Feb 1, 2009 | Dec 7, 2015 | 11 | United States |
| Arm | Type | Description |
|---|---|---|
| Arm A | ACTIVE_COMPARATOR | Tanespimycin + Bortezomib |
| Arm B | ACTIVE_COMPARATOR | Bortezomib |
| tanespimycin and bortezomib | EXPERIMENTAL | A patient will receive a standard dose of bortezomib followed by a high dose of tanespimycin. |
| bortezomib and tanespimycin | EXPERIMENTAL | A patient will receive a standard dose of bortezomib followed by a mid dose of tanespimycin. |
| bortezomib tanespimycin | EXPERIMENTAL | A patient will receive a standard dose of bortezomib followed by a low dose of tanespimycin. |
| Name | Type | Description |
|---|---|---|
| Tanespimycin | DRUG | Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion |
| Bortezomib | DRUG | Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus |
Inclusion Criteria: * Good Performance Status * Documented evidence of multiple myeloma * Documented progression of disease after initial response to one line of therapy * Measurable disease (serum M-protein \>.5g/dl or \> 200 mg urinary M protein excretion) Exclusion Criteria: * Prior treatment ...